UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 99.

Noguera-Julian, M; Cozzi-Lepri, A; Di Giallonardo, F; Schuurman, R; Däumer, M; Aitken, S; Ceccherini-Silberstein, F; D'Arminio Monforte, A; Geretti, A M; Booth, C L; Kaiser, R; Michalik, C; Jansen, K; Masquelier, B; Bellecave, P; Kouyos, R D; Castro, E; Furrer, H; Schultze, A; Günthard, H F; Brun-Vezinet, F; Metzner, K J; Paredes, R (2016). Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 22(2):191-200.

Schaerer, V; Haubitz, S; Kovari, H; Ledergerber, B; Ambrosioni, J; Cavassini, M; Stoeckle, M; Schmid, P; Decosterd, L; Aouri, M; Böni, J; Günthard, H F; Furrer, H; Metzner, K J; Fehr, J; Rauch, A (2015). Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Medicine, 16(10):599-607.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

Ledergerber, B; Costagliola, D; Lodwick, R; Torti, C; van Sighem, A; Podzamczer, D; Mocroft, A; Dorrucci, M; Masquelier, B; Günthard, H F; de Luca, A; Michalik, C (2013). Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 207(5):759-767.

Achermann, Y; Frauenfelder, T; Obrist, S; Zaugg, K; Corti, N; Günthard, H F (2012). A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Reports:5 pages.

Bonetti, N R; Namdar, M; Günthard, H F; Gruner, C; Greutmann, M; Steffel, J; Hürlimann, D; Ruef, C; Tanner, F C; Jenni, R; Biaggi, P (2012). Early versus late initial echocardiographic assessment in infective endocarditis: similar findings and no difference in clinical outcome. Cardiovascular Medicine, 15(11):317-324.

Stadler, T; Kouyos, R; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Joos, B; Rieder, P; Xie, D; Günthard, H F; Drummond, A J; Bonhoeffer, S (2012). Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 29(1):347-357.

Stern, M; Czaja, K; Rauch, A; Rickenbach, M; Günthard, H F; Battegay, M; Fellay, J; Hirschel, B; Hess, C (2012). HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. HIV Medicine, 13(10):589-595.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Herbeck, J T; Müller, V; Maust, B S; Ledergerber, B; Torti, C; Di Giambenedetto, S; Gras, L; Günthard, H F; Jacobson, L P; Mullins, J I; Gottlieb, G S (2012). Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS, 26(2):193-205.

Krones, T; Rüegg, C A; Günthard, H F; Rid (Schulz-Baldes), Annette; Wild, V (2012). Kommentar I zum Fall: „Heimlicher Transfer von HIV-Medikamenten nach Afrika“. Ethik in der Medizin, 24(1):59-61.

Scherrer, A U; von Wyl, V; Götte, M; Klimkait, T; Cellerai, C; Yerly, S; Böni, J; Held, L; Ledergerber, B; Günthard, H F (2012). Polymorphic mutations associated with the emergence of the multi-nucleoside/tide resistance mutations 69 insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes, 59(2):105-112.

Wandeler, G; Keiser, O; Hirschel, B; Günthard, H F; Bernasconi, E; Battegay, M; Clerc, O; Vernazza, P L; Furrer, H (2011). A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS ONE, 6(12):e27903.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Rieder, P; Joos, B; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Rauch, A; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases, 52(4):532-539.

Kouyos, R D; von Wyl, V; Hinkley, T; Petropoulos, C J; Haddad, M; Whitcomb, J M; Böni, J; Yerly, S; Cellerai, C; Klimkait, T; Günthard, H F; Bonhoeffer, S (2011). Assessing predicted HIV-1 replicative capacity in a clinical setting. PLoS Pathogens, 7(11):e1002321.

Lubomirov, R; Colombo, S; di Iulio, J; Ledergerber, B; Martinez, R; Cavassini, M; Hirschel, B; Bernasconi, E; Elzi, L; Vernazza, P; Furrer, H; Günthard, H F; Telenti, A (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. Journal of Infectious Diseases, 203(2):246-257.

Rieder, P; Joos, B; Scherrer, A U; Kuster, H; Braun, D; Grube, C; Niederöst, B; Leemann, C; Gianella, S; Metzner, K J; Böni, J; Weber, R; Günthard, H F (2011). Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clinical Infectious Diseases, 53(12):1271-1279.

Mugavero, M J; May, M; Ribaudo, H J; Gulick, R M; Riddler, S A; Haubrich, R; Napravnik, S; Abgrall, S; Phillips, A; Harris, R; Gill, M J; de Wolf, F; Hogg, R; Günthard, H F; Chêne, G; D'Arminio Monforte, A; Guest, J L; Smith, C; Murillas, J; Berenguer, J; Wyen, C; Domingo, P; Kitahata, M M; Sterne, J A C; Saag, M S (2011). Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. Journal of Acquired Immune Deficiency Syndromes, 58(3):253-260.

Rotger, M; Dalmau, J; Rauch, A; McLaren, P; Bosinger, S E; Martinez, R; Sandler, N G; Roque, A; Liebner, J; Battegay, M; Bernasconi, E; Descombes, P; Erkizia, I; Fellay, J; Hirschel, B; Miró, J M; Palou, E; Hoffmann, M; Massanella, M; Blanco, J; Woods, M; Günthard, H F; de Bakker, P; Douek, D C; Silvestri, G; Martinez-Picado, J; Telenti, A (2011). Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 121(6):2391-2400.

von Wyl, V; Gianella, S; Fischer, M; Niederoest, B; Kuster, H; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE, 6(11):e27463.

Gianella, S; von Wyl, V; Fischer, M; Niederoest, B; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antiviral Therapy, 16(4):535-545.

Wittkop, L; Günthard, H F; de Wolf, F; Dunn, D; Cozzi-Lepri, A; de Luca, A; Kücherer, C; Obel, N; von Wyl, V; Masquelier, B; Stephan, C; Torti, C; Antinori, A; García, F; Judd, A; Porter, K; Thiébaut, R; Castro, H; van Sighem, A I; Colin, C; Kjaer, J; Lundgren, J D; Paredes, R; Pozniak, A; Clotet, B; Phillips, A; Pillay, D; Chêne, G (2011). Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, 11(5):363-371.

di Iulio, J; Ciuffi, A; Fitzmaurice, K; Kelleher, D; Rotger, M; Fellay, J; Martinez, R; Pulit, S; Furrer, H; Günthard, H F; Battegay, M; Bernasconi, E; Schmid, P; Hirschel, B; Barnes, E; Klenerman, P; Telenti, A; Rauch, A (2011). Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology, 53(5):1446-1454.

Scherrer, A U; Ledergerber, B; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Rauch, A; Hirschel, B; Cavassini, M; Elzi, L; Vernazza, P L; Bernasconi, E; Held, L; Günthard, H F (2011). Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical Infectious Diseases, 53(11):1143-1152.

Rusert, P; Krarup, A; Magnus, C; Brandenberg, O F; Weber, J; Ehlert, A K; Regoes, R R; Günthard, H F; Trkola, A (2011). Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Journal of Experimental Medicine, 208(7):1419-1433.

Ruprecht, C R; Krarup, A; Reynell, L; Mann, A M; Brandenberg, O F; Berlinger, L; Abela, I A; Regoes, R R; Günthard, H F; Rusert, P; Trkola, A (2011). MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Journal of Experimental Medicine, 208(3):439-454.

Ortiz, M; Poloni, E S; Furrer, H; Kovari, H; Martinez, R; Arnedo, M; Elzi, L; Bernasconi, E; Vernazza, P; Hirschel, B; Cavassini, M; Ledergerber, B; Günthard, H F; Telenti, A; Tarr, P E (2011). No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Journal of Infectious Diseases, 203(5):620-624.

Scherrer, A U; von Wyl, V; Joos, B; Klimkait, T; Bürgisser, P; Yerly, S; Böni, J; Ledergerber, B; Günthard, H F (2011). Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. Journal of Infectious Diseases, 203(6):791-797.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

Haas, A; Zimmermann, K; Graw, F; Slack, E; Rusert, P; Ledergerber, B; Bossart, W; Weber, R; Thurnheer, M C; Battegay, M; Hirschel, B; Vernazza, P; Patuto, N; Macpherson, A J; Günthard, H F; Oxenius, A (2011). Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 60(11):1506-1519.

von Wyl, V; Kouyos, R D; Yerly, S; Böni, J; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Staehelin, C; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. Journal of Infectious Diseases, 204(7):1095-1103.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Glass, T R; Battegay, M; Cavassini, M; De Geest, S; Furrer, H; Vernazza, P L; Hirschel, B; Bernasconi, E; Rickenbach, M; Günthard, H F; Bucher, H C (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2):197-203.

Kovari, H; Ebnöther, C; Schweiger, A; Berther, N; Kuster, H; Günthard, H F (2010). Pulmonary toxoplasmosis, a rare but severe manifestation of a common opportunistic infection in late HIV presenters: report of two cases. Infection, 38(2):141-144.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Thompson, M A; Aberg, J A; Cahn, P; Montaner, J S G; Rizzardini, G; Telenti, A; Gatell, J M; Günthard, H F; Hammer, S M; Hirsch, M S; Jacobsen, D M; Reiss, P; Richman, D D; Volberding, P A; Yeni, P; Schooley, R T (2010). Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA: The Journal of the American Medical Association, 304(3):321-333.

Braun, D; Horovitz, A; Jenni, R; Bertea, M; Günthard, H F (2010). Aortic homograft endocarditis caused by Cardiobacterium hominis and complicated by agranulocytosis due to ceftriaxone. BMJ Case Reports:bcr.04.2010.2894.

Joos, B; Rieder, P; Fischer, M; Kuster, H; Rusert, P; Trkola, A; Pillai, S K; Wong, J K; Weber, R; Günthard, H F (2010). Association between specific HIV-1 Env traits and virologic control in vivo. Infection, Genetics and Evolution, 10(3):365-372.

Rohrbach, J; Robinson, N; Harcourt, G; Hammond, E; Gaudieri, S; Gorgievski, M; Telenti, A; Keiser, O; Günthard, H F; Hirschel, B; Hoffmann, M; Bernasconi, E; Battegay, M; Furrer, H; Klenerman, P; Rauch, A (2010). Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 59(9):1252-1258.

Schoeni-Affolter, F; Ledergerber, B; Rickenbach, M; Rudin, C; Günthard, H F; Telenti, A; Furrer, H; Yerly, S; Francioli, P (2010). Cohort profile: the Swiss HIV Cohort study. International Journal of Epidemiology, 39(5):1179-1189.

Herold, M A; Günthard, H F (2010). Cushing-Syndrom nach Steroid-Infiltration bei zwei behandelten HIV-infizierten Patienten. Praxis, 99(14):863-865.

Yukl, S A; Gianella, S; Sinclair, E; Epling, L; Li, Q; Duan, L; Choi, A L M; Girling, V; Ho, T; Li, P; Fujimoto, K; Lampiris, H; Hare, C B; Pandori, M; Haase, A T; Günthard, H F; Fischer, M; Shergill, A K; McQuaid, K; Havlir, D V; Wong, J K (2010). Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. Journal of Infectious Diseases, 202(10):1553-1561.

Yukl, S A; Shergill, A K; McQuaid, K; Gianella, S; Lampiris, H; Hare, C B; Pandori, M; Sinclair, E; Günthard, H F; Fischer, M; Wong, J K; Havlir, D V (2010). Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS, 24(16):2451-2460.

Metzner, K J; Rauch, P; von Wyl, V; Leemann, C; Grube, C; Kuster, H; Böni, J; Weber, R; Günthard, H F (2010). Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. Journal of Infectious Diseases, 201(7):1063-1071.

von Wyl, V; Ehteshami, M; Symons, J; Bürgisser, P; Nijhuis, M; Demeter, L M; Yerly, S; Böni, J; Klimkait, T; Schuurman, R; Ledergerber, B; Götte, M; Günthard, H F (2010). Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. Journal of Infectious Diseases, 201(7):1054-1062.

Barnes, E; Flanagan, P; Brown, A; Robinson, N; Brown, H; McClure, M; Oxenius, A; Collier, J; Weber, J; Günthard, H F; Hirschel, B; Fidler, S; Phillips, R; Frater, J (2010). Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. Journal of Infectious Diseases, 202(10):1482-1485.

Rauch, A; Kutalik, Z; Descombes, P; Cai, T; Di Iulio, J; Mueller, T; Bochud, M; Battegay, M; Bernasconi, E; Borovicka, J; Colombo, S; Cerny, A; Dufour, J F; Furrer, H; Günthard, H F; Heim, M; Hirschel, B; Malinverni, R; Moradpour, D; Müllhaupt, B; Witteck, A; Beckmann, J S; Berg, T; Bergmann, S; Negro, F; Telenti, A; Bochud, P Y (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4):1338-1338-1345.e7 .

Rotger, M; Dang, K K; Fellay, J; Heinzen, E L; Feng, S; Descombes, P; Shianna, K V; Ge, D; Günthard, H F; Goldstein, D B; Telenti, A (2010). Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathogens, 6(2):e1000781.

Haas, A; Rehr, M; Graw, F; Rusert, P; Bossart, W; Kuster, H; Trkola, A; Günthard, H F; Oxenius, A (2010). HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses. EMBO Molecular Medicine, 2(6):231-244.

von Wyl, V; Ehteshami, M; Demeter, L M; Bürgisser, P; Nijhuis, M; Symons, J; Yerly, S; Böni, J; Klimkait, T; Schuurman, R; Ledergerber, B; Götte, M; Günthard, H F (2010). HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clinical Infectious Diseases, 51(5):620-628.

Rieder, P; Joos, B; von Wyl, V; Kuster, H; Grube, C; Leemann, C; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Weber, R; Fischer, M; Günthard, H F (2010). HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS, 24(8):1177-1183.

Cusini, A; Günthard, H F; Stussi, G; Schwarz, U; Fehr, T; Grueter, E; Meerbach, A; Bossart, W; Schaer, D J; Rudiger, A (2010). Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. Infection, 38(5):423-426.

Casado, C; Colombo, S; Rauch, A; Martínez, R; Günthard, H F; Garcia, S; Rodríguez, C; Del Romero, J; Telenti, A; López-Galíndez, C (2010). Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS ONE, 5(6):e11079.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Osih, R B; Taffé, P; Rickenbach, M; Gayet-Ageron, A; Elzi, L; Fux, C; Opravil, M; Bernasconi, E; Schmid, P; Günthard, H F; Cavassini, M (2010). Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Research and Human Retroviruses, 26(11):1239-1246.

Alizon, S; von Wyl, V; Stadler, T; Kouyos, R D; Yerly, S; Hirschel, B; Böni, J; Shah, C; Klimkait, T; Furrer, H; Rauch, A; Vernazza, P L; Bernasconi, E; Battegay, M; Bürgisser, P; Telenti, A; Günthard, H F; Bonhoeffer, S; Swiss HIV Cohort Study (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathogens, 6(9):e1001123.

Schmid, A; Gianella, S; von Wyl, V; Metzner, K J; Scherrer, A U; Niederöst, B; Althaus, C F; Rieder, P; Grube, C; Joos, B; Weber, R; Fischer, M; Günthard, H F (2010). Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS ONE, 5(10):e13310.

Gutmann, C; Cusini, A; Günthard, H F; Fux, C; Hirschel, B; Decosterd, L A; Cavassini, M; Yerly, S; Vernazza, P L (2010). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS, 24(15):2347-2354.

Althaus, C F; Gianella, S; Rieder, P; von Wyl, V; Kouyos, R D; Niederöst, B; Schmid, A; Metzner, K J; Joos, B; Günthard, H F; Fischer, M (2010). Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. Journal of Virological Methods, 165(2):151-160.

Fayet, A; Béguin, A; Zanolari, B; Cruchon, S; Guignard, N; Telenti, A; Cavassini, M; Günthard, H F; Buclin, T; Biollaz, J; Rochat, B; Decosterd, L A (2009). A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. Journal of Chromatography B, 877(11-12):1057-1069.

Müller, V; von Wyl, V; Yerly, S; Böni, J; Klimkait, T; Bürgisser, P; Ledergerber, B; Günthard, H F; Bonhoeffer, S (2009). African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS, 23(10):1269-1276.

Fellay, J; Ge, D; Shianna, K V; Colombo, S; Ledergerber, B; Cirulli, E T; Urban, T J; Zhang, K; Gumbs, C E; Smith, J P; Castagna, A; Cozzi-Lepri, A; De Luca, A; Easterbrook, P; Günthard, H F; Mallal, S; Mussini, C; Dalmau, J; Martinez-Picado, J; Miro, J M; Obel, N; Wolinsky, S M; Martinson, J J; Detels, R; Margolick, J B; Jacobson, L P; Descombes, P; Antonarakis, S E; Beckmann, J S; O'Brien, S J; Letvin, N L; McMichael, A J; Haynes, B F; Carrington, M; Feng, S; Telenti, A; Goldstein, D B (2009). Common genetic variation and the control of HIV-1 in humans. PLoS Genetics, 5(12):e1000791.

Rauch, A; James, I; Pfafferott, K; Nolan, D; Klenerman, P; Cheng, W; Mollison, L; McCaughan, G; Shackel, N; Jeffrey, G P; Baker, R; Freitas, E; Humphreys, I; Furrer, F; Günthard, H F; Hirschel, B; Mallal, S; John, M; Lucas, M; Barnes, E; Gaudieri, S (2009). Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 50(4):1017-1029.

Tschochner, M; Chopra, A; Maiden, T M; Ahmad, I F; James, I; Furrer, H; Günthard, H F; Mallal, S; Rauch, A; John, M (2009). Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antiviral Therapy, 14(7):953-964.

Mann, A M; Rusert, P; Berlinger, L; Kuster, H; Günthard, H F; Trkola, A (2009). HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS, 23(13):1659-1667.

Günthard, H F; Huber, M; Kuster, H; Shah, C; Schüpbach, J; Trkola, A; Böni, J (2009). HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. Clinical Infectious Diseases, 48(11):e117-e120.

Günthard, H F; Kamber, R (2009). Heilung von HIV: Wo stehen wir heute? Swiss Aids News, (2):4-7.

Gaudieri, S; Rauch, A; Pfafferott, K; Barnes, E; Cheng, W; McCaughan, G; Shackel, N; Jeffrey, G P; Mollison, L; Baker, R; Furrer, H; Günthard, H F; Freitas, E; Humphreys, I; Klenerman, P; Mallal, S; James, I; Roberts, S; Nolan, D; Lucas, M (2009). Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology, 49(4):1069-1082.

di Iulio, J; Fayet, A; Arab-Alameddine, M; Rotger, M; Lubomirov, R; Cavassini, M; Furrer, H; Günthard, H F; Colombo, S; Csajka, C; Eap, C B; Decosterd, L A; Telenti, A (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 19(4):300-309.

Cusini, A; Günthard, H F; Weber, R; Huber, M; Kamarashev, J; Bertisch, B; Peter, S; Beck, B (2009). Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral therapy. BMJ Case Reports:bcr0520091904.

Metzner, K J; Giulieri, S G; Knoepfel, S A; Rauch, P; Burgisser, P; Yerly, S; Günthard, H F; Cavassini, M (2009). Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clinical Infectious Diseases, 48(2):239-247.

Isler, M; Huber, M; Günthard, H F; Böni, J (2009). Negativer HIV-Combitest trotz hoher HIV-1 Virämie bei einem Patienten mit akuter HIV-Infektion. Swiss Medical Forum, 9:87-88.

Scherrer, A U; Hasse, B; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Bucher, H C; Ledergerber, B; Günthard, H F (2009). Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Medicine, 10(10):647-656.

Weber, E; Günthard, H F; Schertler, T; Seebach, J D (2009). Spontaneous splenic rupture as manifestation of the immune reconstitution inflammatory syndrome in an HIV type 1 infected patient with tuberculosis. Infection, 37(2):163-165.

Günthard, H F; et al (2009). The European HIV Drug Resistance Guidelines 2009. In: European AIDS Clinical Society. European Guidelines for treatment of HIV. Paris: EACS, online.

Yerly, S; Junier, T; Gayet-Ageron, A; Amari, E B E; von Wyl, V; Günthard, H F; Hirschel, B; Zdobnov, E; Kaiser, L (2009). The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS, 23(11):1415-1423.

Gupta, R K; Hill, A; Sawyer, A W; Cozzi-Lepri, A; von Wyl, V; Yerly, S; Lima, V D; Günthard, H F; Gilks, C; Pillay, D (2009). Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, 9(7):409-447.

Hirsch, M S; Günthard, H F; Schapiro, J M; Brun-Vézinet, F; Clotet, B; Hammer, S M; Johnson, V A; Kuritzkes, D R; Mellors, J W; Pillay, D; Yeni, P G; Jacobsen, D M; Richman, D D (2008). Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clinical Infectious Diseases, 47(2):266-285.

Rauch, A; Nolan, D; Furrer, H; McKinnon, E; John, M; Mallal, S; Gaudieri, S; Günthard, H F; Schmid, P; Battegay, M; Hirschel, B; Telenti, A; James, I (2008). HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clinical Infectious Diseases, 46(12):1921-1925.

von Both, U; Laffer, R; Grube, C; Bossart, W; Gaspert, A; Günthard, H F (2008). Acute cytomegalovirus colitis presenting during primary HIV infection: an unusual case of an immune reconstitution inflammatory syndrome. Clinical Infectious Diseases, 46(4):e38-e40.

Koelsch, K K; Liu, L; Haubrich, R; May, S; Havlir, D; Günthard, H F; Ignacio, C C; Campos-Soto, P; Little, S J; Shafer, R; Robbins, G K; D'Aquila, R T; Kawano, Y; Young, K; Dao, P; Spina, C A; Richman, D D; Wong, J K (2008). Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. Journal of Infectious Diseases, 197(3):411-419.

Trkola, A; Kuster, H; Rusert, P; von Wyl, V; Leemann, C; Weber, R; Stiegler, G; Katinger, H; Joos, B; Günthard, H F (2008). In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. Journal of Virology, 82(3):1591-1599.

Frost, D W; Trkola, A; Günthard, H F; Richman, D D (2008). Antibody responses in primary HIV-1 infection. Current Opinion in HIV and AIDS, 3(1):45-51.

Mugavero, M J; May, M; Harris, R; Saag, M S; Costagliola, D; Egger, M; Phillips, A; Günthard, H F; Dabis, F; Hogg, R; de Wolf, F; Fatkenheuer, G; Gill, M J; Justice, A; D'Arminio Monforte, A; Lampe, F; Miró, J M; Staszewski, S; Sterne, J A C (2008). Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS, 22(18):2481-2492.

Joos, B; Fischer, M; Kuster, H; Pillai, S K; Wong, J K; Böni, J; Hirschel, B; Weber, R; Trkola, A; Günthard, H F (2008). HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(43):16725-16730.

Huber, M; von Wyl, V; Ammann, C G; Kuster, H; Stiegler, G; Katinger, H; Weber, R; Fischer, M; Stoiber, H; Günthard, H F; Trkola, A (2008). Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. Journal of Virology, 82(8):3834-3842.

Colombo, S; Rauch, A; Rotger, M; Fellay, J; Martinez, R; Fux, C; Thurnheer, C; Günthard, H F; Goldstein, D B; Furrer, H; Telenti, A (2008). The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. Journal of Infectious Diseases, 198(6):864-867.

Yerly, S; von Wyl, V; Ledergerber, B; Böni, J; Schüpbach, J; Bürgisser, P; Klimkait, T; Rickenbach, M; Kaiser, L; Günthard, H F; Perrin, L (2007). Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS, 21(16):2223-2229.

von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, P L; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, H F; Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of Internal Medicine, 167(16):1782-1790.

Sendi, P; Günthard, H F; Simcock, M; Ledergerber, B; Schüpbach, J; Battegay, M (2007). Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE, 2(1):e173.

Schüpbach, J; Tomasik, Z; Knuchel, M C; Opravil, M; Günthard, H F; Nadal, D; Böni, J (2006). Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. Journal of Medical Virology, 78(8):1003-1010.

Simcock, M; Sendi, P; Ledergerber, B; Keller, T; Schüpbach, J; Battegay, M; Günthard, H F (2006). A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antiviral Therapy, 11(3):305-314.

Schüpbach, J; Günthard, H F; Joos, B; Fischer, M B; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(3):250-256.

Aceto, L; Karrer, U; Grube, Ch; Oberholzer, R; Hasse, B; Presterl, E; Böni, J; Kuster, H; Trkola, A; Weber, R; Günthard, H F (2005). Die akute HIV-1-Infektion in Zürich: 2002–2004. Praxis, 94(32):1199-1205.

Joos, B; Trkola, A; Fischer, M; Kuster, H; Rusert, P; Leemann, C; Böni, J; Oxenius, A; Price, D A; Phillips, R E; Wong, J K; Hirschel, B; Weber, R; Günthard, H F (2005). Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. Journal of Virology, 79(14):9026-9037.

Haupts, S; Ledergerber, B; Böni, J; Schüpbach, J; Kronenberg, A; Opravil, M; Flepp, M; Speck, R F; Grube, C; Rentsch, K; Weber, R; Günthard, H F (2003). Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 8(5):443-454.

Schüpbach, J; Böni, J; Bisset, L R; Tomasik, Z; Fischer, M; Günthard, H F; Ledergerber, B; Opravil, M (2003). HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 33(3):292-299.

Hasse, B; Hummel, Y; Böni, J; Schüpbach, J; Flepp, M; Günthard, H F (2003). 25-jähriger therapienaiver Patient mit einem dreiklassenresistenten HI-Virus. Praxis, 92(13):601-605.

Fischer, M; Günthard, H F; Opravil, M; Joos, B; Huber, W; Bisset, L R; Ott, P; Böni, J; Weber, R; Cone, R W (2000). Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Research and Human Retroviruses, 16(12):1135-1140.

This list was generated on Thu Jul 27 23:53:56 2017 CEST.